Surface Oncology, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SURF research report →
Companywww.surfaceoncology.com
Surface Oncology, Inc. , a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8.
- CEO
- Lisa McGrath
- IPO
- 2018
- Employees
- 35
- HQ
- Cambridge, MA, US
Price Chart
Valuation
- Market Cap
- $65.08M
- P/E
- -0.91
- P/S
- 2.17
- P/B
- 0.64
- EV/EBITDA
- -1.13
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- -206.23%
- Net Margin
- -217.68%
- ROE
- -61.52%
- ROIC
- -41.40%
Growth & Income
- Revenue
- $30.00M · 1016.49%
- Net Income
- $-65,303,000 · 17.82%
- EPS
- $-1.17 · 35.00%
- Op Income
- $-61,869,000
- FCF YoY
- 3.87%
Performance & Tape
- 52W High
- $1.43
- 52W Low
- $0.56
- 50D MA
- $0.96
- 200D MA
- $0.82
- Beta
- 1.75
- Avg Volume
- 798.15K
Get TickerSpark's AI analysis on SURF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 8, 23 | Sigal Charles Elliott | sell | 113,636 |
| Sep 8, 23 | Sigal Charles Elliott | sell | 45,453 |
| Sep 8, 23 | Adams Chandra | sell | 50,000 |
| Sep 8, 23 | Adams Chandra | sell | 23,884 |
| Sep 8, 23 | RATH HENRY C. | sell | 44,971 |
| Sep 8, 23 | RATH HENRY C. | sell | 150,000 |
| Sep 8, 23 | Palombella Vito J. | sell | 87,212 |
| Sep 8, 23 | Palombella Vito J. | sell | 150,000 |
| Sep 8, 23 | Goater Jeff | sell | 129,222 |
| Sep 8, 23 | FEES JESSICA | sell | 101,915 |
Our SURF Coverage
We haven't published any research on SURF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SURF Report →